| Literature DB >> 12370366 |
Yan Xiu1, Kazuhiro Nakamura, Masaaki Abe, Na Li, Xiang Shu Wen, Yi Jiang, Danqing Zhang, Hiromichi Tsurui, Shuji Matsuoka, Yoshitomo Hamano, Hiroyuki Fujii, Masao Ono, Toshiyuki Takai, Toshibumi Shimokawa, Chisei Ra, Toshikazu Shirai, Sachiko Hirose.
Abstract
FcgammaRIIB1 molecules serve as negative feedback regulator for B cell Ag receptor-elicited activation of B cells; thus, any impaired FcgammaRIIB1 function may possibly be related to aberrant B cell activation. We earlier found deletion polymorphism in the Fcgr2b promoter region among mouse strains in which systemic autoimmune disease-prone NZB, BXSB, MRL, and autoimmune diabetes-prone nonobese diabetic, but not NZW, BALB/c, and C57BL/6 mice have two identical deletion sites, consisting of 13 and 3 nucleotides. In this study, we established congenic C57BL/6 mice for NZB-type Fcgr2b allele and found that NZB-type allele down-regulates FcgammaRIIB1 expression levels in germinal center B cells and up-regulates IgG Ab responses. We did luciferase reporter assays to determine whether NZB-type deletion polymorphism affects transcriptional regulation of Fcgr2b gene. Although NZW- and BALB/c-derived segments from position -302 to +585 of Fcgr2b upstream region produced significant levels of luciferase activities, only a limited activity was detected in the NZB-derived sequence. EMSA and Southwestern analysis revealed that defect in transcription activity in the NZB-derived segment is likely due to absence of transactivation by AP-4, which binds to the polymorphic 13 nucleotide deletion site. Our data imply that because of the deficient AP-4 binding, the NZB-type Fcgr2b allele polymorphism results in up-regulation of IgG Ab responses through down-regulation of FcgammaRIIB1 expression levels in germinal center B cells, and that such polymorphism may possibly form the basis of autoimmune susceptibility in combination with other background contributing genes.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12370366 DOI: 10.4049/jimmunol.169.8.4340
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422